Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey
Open Access
- 1 March 2019
- journal article
- research article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 11 (1), 94-99
- https://doi.org/10.4274/jcrpe.galenos.2018.2018.0134
Abstract
Inactivating autosomal recessive mutations in fibroblast growth factor 23 (FGF23), klotho (KL) and polypeptide N-acetylgalactosaminotransferase 3 (GALNT3) genes lead to a rare disorder, hyperphosphatemic familial tumoral calcinosis (HFTC). Patients with HFTC present with hyperphosphatemia and tumor like soft tissue calcifications. Although 78% of patients develop their first symptoms between the ages of 2-13 years, diagnosis is usually delayed until adulthood. Some individuals with the same genetic defect develop a condition named hyperphosphatemic hyperostosis syndrome. Herein we report two siblings suffering from periarticular, warm, hard and tender subcutaneous masses. Subcutaneous calcifications were present on X-ray and biopsy results were consistent with calcinosis in both patients. Laboratory results showed marked hyperphosphatemia and elevated renal tubular phosphate reabsorption rates, normal renal function tests and normal serum 25-hydroxyvitamin D levels. Thus, we suspected HFTC and performed next generation sequencing for the GALNT3 gene, reported as the most frequent cause. A novel homozygote P85Rfs*6 (c.254_255delCT) mutation in GALNT3 was identified in both siblings. Our report adds two new patients to the literature about this rare genetic disease and suggests that small deletions in the GALNT3 gene may be related with HFTC phenotype.Keywords
This publication has 20 references indexed in Scilit:
- Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3mutation; case report and review of the literatureBMC Genomic Data, 2014
- Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanismsAmerican Journal of Medical Genetics Part A, 2014
- Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutationsAmerican Journal of Medical Genetics Part A, 2010
- A case of familial tumoral calcinosis/hyperostosis–hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic featuresOsteoporosis International, 2008
- Tumoral Calcinosis Presenting with Eyelid Calcifications due to Novel Missense Mutations in the Glycosyl Transferase Domain of theGALNT3GeneJournal of Clinical Endocrinology & Metabolism, 2006
- The Role of Mutant UDP-N-Acetyl-α-d-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral CalcinosisJournal of Clinical Endocrinology & Metabolism, 2006
- Polypeptide GalNAc-transferase T3 and Familial Tumoral CalcinosisOnline Journal of Public Health Informatics, 2006
- A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcificationHuman Genetics, 2005
- An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemiaHuman Molecular Genetics, 2004
- Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosisNature Genetics, 2004